November 11, 2026 · JAMA · DOI: 10.1001/jama.2026.19809

HOPO 14-1, an Oral Actinide Chelator: A Phase 1 Nonrandomized Clinical Trial.

Listen to this summary

This phase 1 nonrandomized trial asked whether a single oral dose of HOPO 14-1, an orally administered actinide chelator, is safe and tolerable in healthy adults, and how it is absorbed and excreted. In 42 participants across seven dose levels (100 mg to 7500 mg), there were no serious adverse events or dose-limiting toxicities, with mild-to-moderate gastrointestinal effects (mainly diarrhea and vomiting) becoming most prominent at the highest doses. The drug was rapidly absorbed, showed greater-than-proportional increases in exposure at higher doses, and was eliminated mainly in feces, with minimal urinary excretion.

Sascha N Goonewardena, Laura Atleski, Deborah I Bunin, Anna M Furimsky, Sandra Pui, Carol E Green, Polly Y Chang

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play